Known targets — ChEMBL curated mechanism
The experimentally established mechanism targets of Pravastatin. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HMGCR known ✓ | P04035 | 9/20 | 1.00 |
| ▸ | SLCO1B1 | Q9Y6L6 | 4/20 | 1.00 |
| ▸ | SLC22A8 | Q8TCC7 | 1/20 | 1.00 |
| ▸ | SLCO1B3 | Q9NPD5 | 1/20 | 1.00 |
| ▸ | ALOX15 | P16050 | 2/20 | 0.84 |
| ▸ | HDAC1 | Q13547 | 3/20 | 0.71 |
| ▸ | HDAC2 | Q92769 | 3/20 | 0.71 |
| ▸ | HDAC6 | Q9UBN7 | 3/20 | 0.71 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.55 |
| ▸ | ABCB11 | O95342 | 1/20 | 0.55 |
| ▸ | LMNA | P02545 | 1/20 | 0.55 |
| ▸ | ITGB2 | P05107 | 1/20 | 0.55 |
| ▸ | ICAM1 | P05362 | 1/20 | 0.55 |
| ▸ | PGR | P06401 | 1/20 | 0.55 |
| ▸ | ABCB1 | P08183 | 1/20 | 0.55 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.55 |
| ▸ | ADORA3 | P0DMS8 | 1/20 | 0.55 |
| ▸ | MAPT | P10636 | 1/20 | 0.55 |
| ▸ | ADRB3 | P13945 | 1/20 | 0.55 |
| ▸ | TSHR | P16473 | 1/20 | 0.55 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Pravastatin SCHEMBL1683285 | 1.00 | HMGCR (1.00) | HMGCRSLCO1B1SLC22A8SLCO1B3ALOX15 | |
| Pravastatin SCHEMBL13575802 | 1.00 | HMGCR (1.00) | HMGCRSLCO1B1SLC22A8SLCO1B3ALOX15 | |
| Pravastatin SCHEMBL13318941 | 1.00 | HMGCR (1.00) | HMGCRSLCO1B1SLC22A8SLCO1B3ALOX15 | |
| Pravastatin SCHEMBL13743095 | 1.00 | HMGCR (1.00) | HMGCRSLCO1B1SLC22A8SLCO1B3ALOX15 | |
| Pravastatin SCHEMBL13198584 | 1.00 | HMGCR (1.00) | HMGCRSLCO1B1SLC22A8SLCO1B3ALOX15 | |
| Pravastatin SCHEMBL23936980 | 1.00 | HMGCR (1.00) | HMGCRSLCO1B1SLC22A8SLCO1B3ALOX15 | |
| Pravastatin SCHEMBL14430866 | 1.00 | HMGCR (1.00) | HMGCRSLCO1B1SLC22A8SLCO1B3ALOX15 | |
| Pravastatin SCHEMBL2305070 | 1.00 | HMGCR (1.00) | HMGCRSLCO1B1SLC22A8SLCO1B3ALOX15 | |
| Pravastatin SCHEMBL967719 | 1.00 | HMGCR (1.00) | HMGCRSLCO1B1SLC22A8SLCO1B3ALOX15 | |
| Pravastatin SCHEMBL14621551 | 1.00 | HMGCR (1.00) | HMGCRSLCO1B1SLC22A8SLCO1B3ALOX15 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 11 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2024128125-A1 | THERAPEUTIC AGENT FOR CHRONIC RESPIRATORY DISEASES | 学校法人慈恵大学 | 2024-06-20 | — | — | WO | disclosed |
| CN-110913871-B | Generation of mammalian T cell activation inducible synthetic promoters (SYN+PRO) to improve T cell therapy | 西雅图儿童医院（DBA西雅图儿童研究所） | 2024-02-23 | — | — | CN | disclosed |
| CN-116712552-A | Methods and compositions for treating herpes virus-induced conditions | 波士顿大学托管委员会 | 2023-09-08 | — | — | CN | disclosed |
| CN-109310884-B | Method for treating or preventing liver diseases | CSL有限公司 | 2022-10-28 | — | — | CN | disclosed |
| US-20190321291-A1 | 3D Printing and Drug Delivery | BIOGELX LIMITED (GB) | 2019-10-24 | — | — | US | disclosed |
| WO-2018104537-A1 | 3D PRINTING AND DRUG DELIVERY | BIOGELX LIMITED (GB) | 2018-06-14 | — | — | WO | disclosed |
| US-20170252338-A1 | MEDICINE | KOWA COMPANY, LTD. (JP) | 2017-09-07 | — | — | US | disclosed |
| US-7262218-B2 | Forms of pravastatin sodium | TEVA GYOGYSZERGYAR ZARTKORUEN MUKODO RESZVENYTARSASAG (HU) | 2007-08-28 | — | — | US | disclosed |
| US-7262218-B2 | Forms of pravastatin sodium | TEVA GYOGYSZERGYAR ZARTKORUEN MUKODO RESZVENYTARSASAG (HU) | 2007-08-28 | — | — | US | disclosed |
| US-20070197633-A1 | Novel forms of pravastatin sodium | TEVA GYOGYSZERGYAR ZARTKORUEN MUKODO RESZVENYTARSASAG (HU) | 2007-08-23 | — | — | US | disclosed |
| US-20070197633-A1 | Novel forms of pravastatin sodium | TEVA GYOGYSZERGYAR ZARTKORUEN MUKODO RESZVENYTARSASAG (HU) | 2007-08-23 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20170252338-A1 | MEDICINE | HMGCR, PCSK9, CYP46A1 | HMGCR 1/4885SLCO1B1 253/4885SLC22A8 290/4885 |
| US-20190321291-A1 | 3D Printing and Drug Delivery | HTR3D, SLC34A3, ABCB1 | HMGCR 3693/4885SLCO1B1 315/4885SLC22A8 134/4885 |
| US-20070197633-A1 | Novel forms of pravastatin sodium | HMGCR, PCSK9, CYP4A11 | HMGCR 1/4885SLCO1B1 383/4885SLC22A8 376/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.